Drugs / Human Acellular Vessel (HAV)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02887859 | Dec 2016 → Dec 2020 | peripheral arterial disease | Humacyte, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT03005418 | Sep 2018 → Sep 2027 expected | vascular disorder | Humacyte, Inc. | Active not recruiting | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Acellular Vessel (HAV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03005418 ↗ |
| Modality | Other / unclassified | “The ATEV is a bioengineered vascular conduit grown from human vascular cells, available off the shelf, and implantable without immunosuppression.” PMID 39565635 ↗ Feb 2025 |
| Route | Other | “Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques” NCT02887859 ↗ |